Comparison of Commonly Used Antidepressants

Lead author: Beth A. Lesher, Pharm.D., BCPS

-Based on U.S. Prescribing Information and Other Related Sources-

Name	e/ Brand Approved Dose.2					CYP	Additional Information Concurrent administration of an antidepressant with a monoamine-oxidase inhibitor is contraindicated.	
		A	nticholinergic	Arrhythmias	Sedation	Weight Gain	t	
Dopamine Re	euptake Block	ing Agents						
Bupropion/ Wellbutrin Wellbutrin XL Wellbutrin SR Zyban <sup>4</sup>		200 to 450		+			Moderate inhibitor of CYP 2D6	-Contraindicated in patients with or at an increased risk of seizures
Noradrenergi	c Antagonist							
Mirtazapine/ Remeron <sup>5</sup>	Depression	30 to 60	+		+++	+++	No significant CYP inhibition	-Administer dose at bedtime
Selective Sero	otonin Reupta	ke Inhibitors	f					
Citalopram/ Celexa <sup>6</sup>	Depression (Obsessive- compulsive disorder Panic disorder)	20 to 60				+		-Administer a reduced dose (20 mg daily) to the elderly and those with hepatic impairment
Escitalopram/ Lexapro <sup>7</sup>	Depression Generalized anxiety disorder	10 to 20				+	Moderate inhibitor of CYP 2D6 at higher doses	
Fluoxetine/ Prozac Sarafem <sup>8,9</sup>	Adults Depression Obsessive- compulsive disorder Bulimia Panic disorder Premenstrual dysphoric disorder (Anorexia nervosa Bipolar disorder Premenstrual syndrome)	Adults 20 to 80		-	-	+	Potent inhibitor of CYP 2D6 and 3A4	-Use with thioridazine (Mellaril) is contraindicated - Discontinue fluoxetine 7 days prior to starting weekly fluoxetine EAdminister a reduced dose to the elderly and those with hepatic impairment
	Pediatrics Depression Obsessive- compulsive disorder	Pediatrics 10 to 60						
Fluvoxamine/ Luvox <sup>10</sup>	Adults Obsessive- compulsive disorder (Depression)	Adults 100 to 300				+	Potent inhibitor of CYP 1A2, 2C19, 3A4	-Use with thioridazine and pimozide ( <i>Orap</i> ) is contraindicated

	Adults	Adults				+	Potent	-Use with thioridazine and
Luvox <sup>10</sup>	Obsessive- compulsive disorder (Depression)	100 to 300				7	inhibitor of CYP 1A2, 2C19, 3A4	pimozide (Orap) is contraindicated
	Pediatrics Obsessive- compulsive disorder	Pediatrics 50 to 300						
Paroxetine/ Paxil <sup>11</sup> Paxil CR <sup>12</sup>	Depression Obsessive- compulsive disorder Panic disorder Social anxiety disorder Generalized anxiety disorder Post- traumatic stress disorder Premenstrual dysphoric disorder	20 to 50 25 to 62.5	+		+	++	Potent inhibitor of CYP 2D6	-Use with thioridazine (Mellaril) is contraindicated - Administer a reduced dose (20 mg daily) to the elderly and those with hepatic or severe renal impairment
Sertraline/ Zolofi <sup>13</sup>	Adults Depression Obsessive- compulsive disorder Panic disorder Post- traumatic stress disorder Premenstrual dysphoric disorder Social anxiety disorder	Adults 100 to 200			_	+	CYP 2D6 at	-Use with thioridazine (Mellaril) and pimozide (Orap) is contraindicated -Administer a reduced dose to the elderly and those with hepatic impairment
	Pediatrics Obsessive- compulsive disorder	Pediatrics 25 to 200						
Serotonin No	repinephrine l	Reuptake In	hibitors					
Duloxetine/ Cymbalta <sup>14</sup>	Depression Pain associated with diabetic peripheral neuropathy	40 to 60			+		Inhibits CYP 2D6	-Contraindicated in patients with uncontrolled narrow-angle glaucoma
Venlafaxine/ Effexor <sup>15</sup> Effexor XR <sup>16</sup>	Depression Generalized anxiety disorder Social anxiety disorder	150 to 375 75 to 225	+	+	+		No significant CYP inhibition	-Blood pressure can increase - Reduce starting dose by 50% in moderate hepatic impairment - Reduce daily dose by 25% to 50% in hemodialysis patients
Tricyclic Ant	idepressants							
Amitriptyline/ Elavil <sup>17,18</sup>	Depression (Bulimia nervosa Neuralgia)	100 to 300	++++	+++	++++	++++	No significant CYP inhibition	-Can cause arrhythmias in patients with cardiovascular disorders
Desipramine/ Norpramine <sup>17,</sup>	Depression (Anxiety Bulimia nervosa	100 to 300	+	++	++	+	May inhibit CYP 2D6	-Contraindicated in the acute recovery period following myocardial infarction -Reduce the dose in adolescents and the elderly -Prolongation of the
19	Panic disorder Premenstrual syndrome)							QRS or QT interval can occur a higher doses

	disorder Premenstrual syndrome)							QRS or QT interval can occur at higher doses	
Doxepin/ Adapin Sinequan <sup>17, 20</sup>	Depression and/or anxiety Depression and/or anxiety associated with alcoholism or organic disease (Anxiety, Neuralgia)	100 to 300	+++	++	++++	++++	No significant CYP inhibition	-Drowsiness is common; patients should be warned	
Imipramine/ Tofranil Tofranil PM <sup>17</sup> <sup>21, 22</sup>	nervosa Panic disorder)  Pediatrics	100 to 300	+++	+++	+++	++++	No significant CYP inhibition	-Optimal plasma levels are 200 to 300 ng/mL -Administration following a myocardial infarction is contraindicated - Reduced doses (30-100 mg daily) are recommended for adolescents and the elderly	
	Childhood enuresis	25 to 75							
Nortriptyline/ Aventyl Pamelor <sup>17, 23</sup>	Depression (Smoking cessation)	50 to 150	++	++	++	+	No significant CYP inhibition	-Use with thioridazine (Mellaril) is contraindicated - Optimal plasma levels are 50 to 150 ng/mL -Recommended dose for elderly and adolescent patients is 30 to 50 mg/day	
Serotonin-2 Receptor Antagonists									
Nefazodone/ Serzone <sup>24</sup>	Depression (Panic disorder)	300 to 600	+		+		Potent inhibitor of CYP 3A4	-Concomitant use with pimozide (Orap) and carbamazepine (Tegretol) is contraindindicated-Concomitant use with triazolam (Halcion) is not recommended; decrease triazolam dose by 75% if given with nefazodone -Life-threatening hepatic failure has occurred with nefazodone administration	
<sup>a</sup> Indications are for adults unless otherwise stated. <sup>b</sup> Discontinuation symptoms can occur when antidepressant medications are abruptly stopped. This may be more problematic for drugs with short half-lives such as paroxetine and venlafaxine. However, symptoms can occur when drugs with longer half-lives are stopped such as fluoxetine. Current recommendations are to taper antidepressant doses over several weeks to two to three months. <sup>8c</sup> to ++++, absent or rare to relatively common. <sup>d</sup> Sexual dysfunction can occur with antidepressant therapy. Bupropion, nefazodone, mirtazapine, and amitriptyline are reported to cause the least amount of sexual dysfunction. <sup>2,25</sup> Cutochrome PASO (CVP): CVP 2DG substrates include portriptyline are reported.									

<sup>1</sup>Indications are for adults unless otherwise stated. <sup>b</sup>Discontinuation symptoms can occur when antidepressant medications are abruptly stopped. This may be more problematic for drugs with short half-lives such as paroxetine and venlafaxine. However, symptoms can occur when drugs with longer half-lives are stopped such as fluoxetine. Current recommendations are to taper antidepressant doses over several weeks to two to three months. <sup>8c</sup> – to +++++, absent or rare to relatively common. <sup>d</sup>Sexual dysfunction can occur with antidepressant therapy. Bupropion, nefazodone, mirtazapine, and amitriptyline are reported to cause the least amount of sexual dysfunction. <sup>2,25</sup> Cytochrome P450 (CYP): CYP 2D6 substrates include nortriptyline, amitriptyline, imipramine, propafenone (*Rythmol*), and flecainide (*Tambocor*); CYP 1A2 substrates include warfarin (*Coumadin*), theophylline (*TheoDur*), and propranolol (*Inderal*); CYP 3A4 substrates include amlodipine (*Norvasc*), atorvastatin (*Lipitor*), azole antifungals, carbamazepine (*Tegretol*), cisapride (*Propulsid*), cyclosporine, erythromycin, estrogens, oral contraceptives, felodipine (*Plendil*), HIV protease inhibitors, lovastatin (*Mevacor*), nefazodone (*Serzone*), nifedipine, quinidine, sertraline (*Zoloff*), sildenafil (*Viagra*), tamoxifen (*Nolvadex*), verapamil, warfarin (*Coumadin*), and others. Note: Many of these agents are also CYP substrates and interact with other substrates and inhibitors. See our Detail-Document #150400 for more information. <sup>f</sup>The selective serotonin reuptake inhibitors (SSRI) can cause the serotonin syndrome. Recommendations are to discontinue SSRI therapy and provide supportive therapy. <sup>2</sup>